Multiomics Tumor Evolution Model of NSCLC
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Non-small Cell Lung Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Multiomics Study of Tumor Evolution Characteristics and Prognostic Model in Early-stage Non-small Cell Lung Cancer
Overview
The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.
Detailed description
Lung cancer is the leading cause of cancer-related death globally. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and surgery is still the main treatment strategy. This study will determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.
Primary outcome measures
- Disease-free survival (DFS) [Time frame: Through study completion, an average of 2 years]
- Overall survival (OS) [Time frame: Through study completion, an average of 2 years]
Secondary outcome measures (1)
- Relationship between translational biomarkers and clinical outcome [Time frame: Through study completion, an average of 2 years]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years old;
- Early-stage NSCLC patients underwent radical surgical resection;
- Sufficient tumor tissue and blood sample for study use;
- Available clinical-pathologic data, imaging data and follow-up date;
- Written informed consent.
Exclusion criteria
- History of other malignant tumors;
- Evidence of distant metastasis before surgery;
- Insufficient tumor tissue or blood sample for study use;
- Clinical-pathologic data, imaging data or follow-up date is not available;
- Other judgments by the Investigator that the patient should not participate in the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Peking University People's Hospital — Beijing
Identifiers
NCT: NCT05352035 · 2021-I2M-5-002